PALB2 and pancreatic neoplasm: In a study of comparing prevalence of deleterious germline mutations (BRCA1/2, PALB2, and CDKN2A) in FPC (having two FDRs with pancreatic cancer) and non-FPC (at least two affected relatives, but no FDRs) families, FPC families have more germline mutations (8.0%) than non-FPC families (3.5%) (odds ratio: 2.4; 95% CI: 1.06–5.44; p = 0.03) [7].